NRX Pharmaceuticals Inc NRXP

NAS: NRXP | ISIN: US6294441000   7/05/2024
2,810 USD (-8,17%)
(-8,17%)   7/05/2024

7 mei 2024 · NRx Pharmaceuticals, Inc. (Nasdaq:NRXP) to Report First Quarter 2024 Financial Results on May 14, 2024 · Persbericht

6 mei 2024 · NRx Pharmaceuticals (Nasdaq:NRXP) Announces Final Clinical Trial Results: Superior Safety Combined with Similar Efficacy in the Trial of NRX-101 Compared to Lurasidone in Suicidal Bipolar Depression · Persbericht

30 april 2024 · NRx Pharmaceuticals (Nasdaq:NRXP) Announces Promising Findings in Phase 2b/3 Clinical Trial of NRX-101 vs. Lurasidone for Treatment of Suicidal Bipolar Depression · Persbericht

18 april 2024 · NRx Pharmaceuticals (NASDAQ:NRXP) Receives Notice from Nasdaq that the Company has Demonstrated Compliance with the Bid Price Requirement · Persbericht

18 april 2024 · NRx Pharmaceuticals, Inc. Announces Pricing of $2.0 Million Underwritten Public Offering of Common Stock · Persbericht

17 april 2024 · NRx Pharmaceuticals, Inc. Announces Proposed Underwritten Public Offering of Common Stock · Persbericht

17 april 2024 · NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announces New Data on NRX-101 Demonstrating No Damage to Intestinal and Vaginal Flora in Validated Rodent Models Compared to Standard Antibiotics: Potential Implications for Avoidance of C. Difficile infections · Persbericht

15 april 2024 · NRx Pharmaceuticals (NASDAQ:NRXP) Announces Development of New, Proprietary Formulation of HTX-100 (IV Ketamine) · Persbericht

8 april 2024 · NRx Pharmaceuticals (NASDAQ:NRXP) Announces Data-Lock of Phase 2b/3 Trial of NRX-101 in Suicidal Treatment Resistant Bipolar Depression · Persbericht

1 april 2024 · NRx Pharmaceuticals (Nasdaq:NRXP) Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update · Persbericht

28 maart 2024 · NRx Pharmaceuticals (NASDAQ:NRXP) Reports Preliminary Fourth Quarter and Full Year 2023 Financial Results and Provides Year End Highlights · Persbericht

28 maart 2024 · NRx Pharmaceuticals Announces Reverse Stock Split to Maintain Nasdaq Listing · Persbericht

26 maart 2024 · UPDATE: NRx Pharmaceuticals (NASDAQ: NRXP) to Report Fourth Quarter and Full Year 2023 Financial Results on March 28, 2024 · Persbericht

25 maart 2024 · NRx Pharmaceutical's (NASDAQ:NRXP) Chairman Dr. Jonathan Javitt to Present at the Ketamine 2024 Conference in Oxford, UK · Persbericht

21 maart 2024 · NRx Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results and Provide a Corporate Update on March 28, 2024 · Persbericht

21 maart 2024 · NRx Pharmaceuticals Announces Results of the Vote Held During the Special Meeting of Shareholders · Persbericht

18 maart 2024 · NRx Pharmaceuticals (NASDAQ:NRXP) Announces Plan to Distribute Shares of HOPE Therapeutics and Royalty Rights on Ketamine Sales to Existing NRx Shareholders · Persbericht

12 maart 2024 · NRx Pharmaceuticals (NASDAQ:NRXP) Initiates Strategy to Combat Short Sales · Persbericht

11 maart 2024 · NRx Pharmaceuticals (NASDAQ:NRXP) Completes Memorandum of Understanding and Collaborations with Distribution Partners for HTX-100 (IV Ketamine) · Persbericht

4 maart 2024 · NRx Pharmaceuticals (NASDAQ: NRXP) Announces Last Patient, Last Visit in its Phase 2b/3 Trial of NRX-101 in Suicidal Treatment Resistant Bipolar Depression · Persbericht

Mijn selecties